CAPZA supports Mayoly Spindler in its development strategy
Ipsen CHC includes established brands such as Smecta®, Forlax® and Tanakan®, recognized by practitioners and patients worldwide, and distributed in more than 80 countries.
This acquisition would be in line with Mayoly Spindler’s development strategy. A French, family-owned and independent pharmaceutical group, Mayoly Spindler seeks to become one of the world’s leading gastroenterology and dermocosmetics companies through this acquisition. The company has built its development around specialties that are also recognized worldwide, such as Meteospasmyl®, Probiolog® or Topicrem®, many of which are complementary to Ipsen CHC’s therapeutic solutions.
This transaction would accelerate Mayoly Spindler’s development and strengthen its long-term ambition of being a top ten European OTC drugs players as well as becoming part of the top 5 European OTC gastroenterology drugs provider over the next 10 years. With 2,200 employees across all continents, the new entity would benefit from a strong industrial footprint in France, portfolio complementarities in its therapeutic areas, unique commercial synergies and pooled investments in research and development.
“We are proud to be retained by Ipsen as the acquiror of their CHC business, and we look forward to welcoming their employees in order to build together a leading player in consumer healthcare, relying on world-renowned pharmaceutical specialties, a strong industrial footprint in France and a global presence.” said Jean-Nicolas Vernin, Chairman, and Nicolas Giraud, CEO of Mayoly Spindler.
In addition to the support of the historical banking partners, CAPZA and Caravelle, two French and European financial partners specialized in operations of this scale, will supply part of the funds required to complete this transaction, by acquiring a minority stake in the combined entity.
“We are particularly pleased to support this ambitious growth project in an industry we know well, and to contribute to the creation of a French champion in consumer healthcare.”, commented Lorène Martel, President of Caravelle, Guillaume Basquin and Frédéric Chiche, Partners and Co-Heads of CAPZA Expansion.
The proposed acquisition will be subject to the consultation of employee representative bodies, as well as the finalization of the legal documentation and the customary authorizations, in accordance with the regulations in force. Mayoly Spindler expects to complete the acquisition in the third quarter of 2022.
28Feb’ 2024Gainerie 91 welcomes CAPZA Transition as a shareholderCAPZA supports Gainerie 91 in its development strategyRead more
23Feb’ 2024CAPZA and Bpifrance accelerate the development of IMDEVIMDEV, a leading French medical imaging group, welcomes CAPZA and Bpifrance as minority shareholdersRead more
16Feb’ 2024CAPZA renews its support to EurofeuCAPZA announces the sale of its majority stake in Eurofeu to IK Partners, and reinvests in the new operationRead more
19Jan’ 20242023 reviewCAPZA pursued its mission to support SMEs' sustainable and responsible growthRead more